Eli Lilly and CoHAM:LLY -1.36%98 PS Ratio is 15.28 as of Jul. 02, 2026, which is 96% above its 10-year median of 7.80. GuruFocus rates HAM:LLY with a GF Score™ of 98/100 and a GF Value™ of €1,243.95 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 950 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 91.79% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Eli Lilly and Co's share price is €1056.40.
Eli Lilly and Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €69.14. Hence, Eli Lilly and Co's PS Ratio for today is 15.28.
Warning Sign:
Eli Lilly and Co stock PS Ratio (=14.81) is close to 1-year high of 16.33.
The historical rank and industry rank for Eli Lilly and Co's PS Ratio or its related term are showing as below:
HAM:LLY'
s PS Ratio Range Over the Past 10 Years
Min: 3.45 Med: 7.8 Max: 22.74
Current: 14.81
During the past 13 years, Eli Lilly and Co's highest PS Ratio was 22.74. The lowest was 3.45. And the median was 7.80.
HAM:LLY's PS Ratio is ranked worse than 91.79% of 950
companies
in the Drug Manufacturers industry
Industry Median: 2.27
vs HAM:LLY: 14.81
Eli Lilly and Co has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Eli Lilly and Co was 48.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 31.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 20.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 13.10% per year.
During the past 13 years, Eli Lilly and Co's highest 3-Year average Revenue per Share Growth Rate was 31.90% per year. The lowest was -5.70% per year. And the median was 7.40% per year.
Back to Basics: PS Ratio
Eli Lilly and Co (HAM:LLY) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Eli Lilly and Co PS Ratio Related Terms
Eli Lilly and Co PS Ratio Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Eli Lilly and Co's Share Price of today is €1056.40. Eli Lilly and Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €69.14.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Eli Lilly and Co (HAM:LLY) has a PS Ratio of 15.28 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Eli Lilly and Co and its competitors. This is 96% above median its historical median of 7.80. Over the past decade, Eli Lilly and Co's PS Ratio has ranged from 3.45 to 22.74. According to the industry distribution chart, Eli Lilly and Co ranks #872 out of 950 companies in the Drug Manufacturers industry, placing it in the top 91.8%.
Is Eli Lilly and Co's PS Ratio too high?
Eli Lilly and Co's current PS Ratio of 15.28 is 96% above median its 10-year median of 7.80. Over the past 10 years, this metric has ranged from a low of 3.45 to a high of 22.74. The Drug Manufacturers industry median PS Ratio is 2.27. Eli Lilly and Co's value of 15.28 is 573.1% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #872 out of 950 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's PS Ratio compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #872 out of 950 companies for PS Ratio. This places Eli Lilly and Co in the lower half of its industry. The industry median PS Ratio is 2.27. Eli Lilly and Co's value of 15.28 is 573.1% above this benchmark. Historically, Eli Lilly and Co's own PS Ratio has ranged from 3.45 to 22.74 over the past decade. While the company's 10-year median is 7.80 vs. the industry median of 2.27, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.27, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current PS Ratio of 15.28 is 573.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current PS Ratio is 15.28, which is 96% above median its own 10-year median of 7.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (HAM:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,243.95, compared to a current price of €1,056.40 — trading 15.1% below its estimated fair value. The current PS Ratio is 15.28, which is 96% above median its 10-year median of 7.80 and 573.1% above the Drug Manufacturers industry median of 2.27. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Eli Lilly and Co (HAM:LLY), the current PS Ratio is 15.28 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of €1,056.40 is trading 15.1% below its estimated GF Value™ of €1,243.95.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for HAM:LLY:
PS Ratio: 15.28 (96% above median its 10-year median of 7.80)
GF Value™: €1,243.95 vs. price of €1,056.40 (15.1% below fair value)
Industry Position: 573.1% above the Drug Manufacturers median (#872 of 950)
No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score
Get the complete analysis for HAM:LLY
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:LLY has been successfully added to your 
